NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical
company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the appointment
of Michael Olchaskey, PharmD as Senior Vice President, Head of Regulatory Affairs. Dr. Olchaskey brings over 20
years of global regulatory affairs experience with investigational and commercialized products across a range of CNS disorders,
including schizophrenia, bipolar disorder, depression, Alzheimer’s disease, and Parkinson’s disease.
Dr. Olchaskey has held positions of increasing responsibility and scope in Regulatory Affairs at Allergan plc
over the last 16 years. He has overseen a wide array of submissions and approvals for products, including cariprazine, asenapine,
escitalopram, levomilnacipran, milnacipran, and vilazodone.
Dr. Olchaskey received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degree from Rutgers University.
He also did a Post-Doctoral Fellowship jointly sponsored by Hoffmann La Roche and Rutgers University.
“We are delighted to welcome Dr. Olchaskey to our team. Michael has strong global regulatory strategy experience
for indications relevant to our pipeline and has been involved in over 10 new and 60 supplemental drug approvals. We believe his
expertise further strengthens our leadership in the development of treatments for CNS diseases,” said Dr. Andrew Satlin,
Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies.
“I am enthusiastic about joining the team at Intra-Cellular Therapies and look forward to contributing to
the advancement of the lumateperone programs in schizophrenia and other neuropsychiatric disorders including bipolar disorder,
agitation associated with dementia, and depressive disorders as well as the advancement of ITI-214 and ITI-333,” stated Dr.
Olchaskey.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative
diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug
candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in
patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders.
Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression
and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE)
platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule
in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease and
for the treatment of heart failure.
Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone: 646-440-9333
